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Aims and method To investigate the percentage of patients who commenced
smoking after transferring out of a non-smoking forensic psychiatric unit, the
corresponding clozapine dose adjustments, the eﬀects on plasma clozapine/
norclozapine concentrations and observed changes in mental state. We reviewed the
notes and plasma clozapine/norclozapine concentrations of 46 patients transferred
to medium secure units between July 2008 and December 2013.
Results Thirty-ﬁve patients commenced smoking. Their median clozapine dose was
increased by 50 mg/d. In the non-smokers, the median clozapine dose remained
unchanged. Plasma clozapine/norclozapine concentrations were signiﬁcantly
reduced in smokers despite dosage adjustment. Eighteen patients experienced
deterioration in mental state after transfer; almost all these patients were smokers.
Clinical implications Approximately three-quarters of patients who were
non-smokers by virtue of being in a secure non-smoking environment commenced
smoking after transfer. Monitoring of clozapine serum levels and assessment of
mental state in the immediate period after a change in smoking status is indicated.
Declaration of interest None.
Keywords Clozapine; smoking; relapse.
Clozapine use in schizophrenia
Clozapine is the only antipsychotic licensed for use in
patients with treatment-resistant schizophrenia. It has a
narrow therapeutic index and pre-dose plasma clozapine
concentrations between 0.35 and 0.60 mg/L are associated
with optimal response, although patients may show such a
response at lower or indeed higher plasma concentrations.1
Adverse eﬀects are more likely at plasma concentrations
above 0.6 mg/L.2
Clozapine metabolism
Clozapine is primarily metabolised to its principal plasma
metabolite N-desmethylclozapine (norclozapine) by the
cytochrome P450 (CYP) isoenzyme CYP1A2, with possible
additional contributions by CYP2C9, CYP2C19, CYP2D6
and CYP3A4.3,4 There are signiﬁcant diﬀerences in plasma
concentrations of clozapine between patients receiving the
same dose, owing to factors including age, gender and
exposure to tobacco smoke.5,6 The magnitude of the eﬀects
of the polycyclic aromatic hydrocarbons in tobacco smoke
in increasing CYP1A2 activity are second only to dose on
plasma clozapine concentrations.7 A systematic review of
the eﬀects of smoking cessation on plasma clozapine con-
centrations found clozapine dose reductions of between
30 and 40% were required to achieve pre-cessation concen-
trations.8 Neither the nicotine in cigarettes nor nicotine
replacement therapy products have an eﬀect on clozapine
metabolism.8
Schizophrenia and smoking
Patients with schizophrenia are more likely to smoke cigar-
ettes, and in greater quantity, than the general population.9
An evaluation from a UK forensic psychiatric medium
secure unit found 84% of in-patients were smokers before
the introduction of a smoking ban, and cessation rates
after smoking reduction programmes are less than 7%.10,11
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Ashworth Hospital is a high-security psychiatric hos-
pital serving the population of Northern England and
Wales. The hospital has approximately 200 male in-patients
who are detained under various sections of the Mental
Health Act 1983; none have unsupervised community
leave. The hospital became a non-smoking unit on 1 July
2008. Tobacco products are not permitted in the hospital.
This is a policy that is eﬀectively implemented as all hospital
staﬀ, patients and visitors are subject to rigorous security
measures, including searches in and out of the hospital
and x-ray scanning of personal possessions. Patients no
longer requiring treatment in a high secure unit are trans-
ferred either to prison or to medium secure units. At the
time of this evaluation, all the medium secure units to
which patients were transferred permitted smoking.
Clozapine and smoking
We could ﬁnd no published study that documented changes
in smoking status and clozapine dose requirement after
transferring out of a non-smoking psychiatric unit. We
decided to investigate the percentage of patients who com-
menced smoking after transfer, the corresponding clozapine
dose adjustments performed, the associated eﬀects on
plasma clozapine and norclozapine concentrations and
observed changes in mental state.
Method
The service evaluation was registered within Mersey Care
National Health Service (NHS) Foundation Trust. We iden-
tiﬁed patients prescribed clozapine who were discharged to
medium secure units (both NHS and independent) from
Ashworth Hospital from July 2008 to December 2013.
Patients transferred to a medium secure unit on trial leave
remain under the nominal care of the Responsible
Clinician at Ashworth hospital and are routinely reviewed
by clinical staﬀ from Ashworth Hospital; trial leave is for a
minimum period of 6 months and can be longer, allowing
an opportunity to review case records and changes in smok-
ing status. From the clinical notes we collected data on
clozapine dose, plasma clozapine and norclozapine concen-
trations, smoking status and mental state in the 6 months
pre-transfer and up to 12 months post-transfer. Patients
who were either discharged without a period of trial leave,
or remitted directly to court or prison were excluded.
Plasma clozapine and norclozapine concentrations were
monitored as necessary to help guide clozapine dose adjust-
ment. The last clozapine plasma measurement on ﬁle was
used as a measure of post-transfer plasma clozapine and
norclozapine. Information routinely recorded when request-
ing plasma clozapine assays include the time and date of
sample, time and date of last clozapine dose, clozapine
dose (milligrams per day), mode of administration (tablets
or suspension), duration of clozapine treatment, age
(years), gender, body weight (kilograms), smoking status
(yes/no) and other relevant information that could aid inter-
pretation of the result, such as co-prescribed drugs and the
reason for the assay request.
Statistical signiﬁcance of analysed data was calculated
using paired t-tests and Fisher’s exact test as appropriate.
Ethical approval
The service evaluation was registered within Mersey Care
NHS Foundation Trust. Ethical approval was not required;
no individual patient is described.
Results
Forty-six male patients with complete data were identi-
ﬁed. All had a diagnosis of schizophrenia (ICD-10 F20).12
Ethnicity was White British (n = 27), White Irish (n = 2),
Black Caribbean (n = 3), Black African (n = 2), other Black
background (n = 4), Pakistani (n = 2), Indian (n = 1), other
Asian background (n = 1), and other mixed background
(n = 4). The median age at the start of trial leave was
37.1 years (range, 24.8–56.0 years).
Plasma clozapine and norclozapine concentrations had
been measured in all patients before transfer (median time
before transfer, 89.5 days; range, 1–315 days). The median
number of plasma clozapine assays performed after transfer
to a medium secure unit was 2 (range, 1–9). Plasma cloza-
pine was ﬁrst measured on average 45 days post-transfer
(range, 2–345 days). A total of 72% of patients had plasma
clozapine and norclozapine measured within 1 month of
starting trial leave; this increased to 87% of patients at
3 months post-transfer.
Thirty-ﬁve patients (76%) commenced smoking after
transfer and eleven (24%) remained non-smokers
(Table 1). The average duration of follow-up was 6.6 months
in both the smoking and non-smoking groups.
In the smoking group the median clozapine dose before
transfer was 275 mg/d and this increased to 350 mg/d after
Table 1 Comparison of pre- and post-transfer data: clozapine dose (mg/d) and clozapine concentration (mg/L)
Smokers (N = 35) Non-smokers (N = 11)
Pre-transfer Post-transfer P-valuea Pre-transfer Post-transfer P-valuea
Median (range) clozapine dose (mg/d) 275 (150–550) 350 (175–750) 250 (125–500) 250 (200–400)
Mean (s.d.) clozapine dose (mg/d) 306 (101) 376 (133) <0.01 270 (104) 282 (67) 0.54
Mean (s.d.) plasma clozapine
concentration (mg/L)
0.58 (0.20) 0.43 (0.15) <0.01 0.47 (0.16) 0.40 (0.14) 0.11
Mean (s.d.) plasma norclozapine
concentration (mg/L)
0.34 (0.12) 0.28 (0.12) <0.01 0.33 (0.10) 0.29 (0.11) 0.03
a. Two-tailed paired t-test.
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transfer; an increase of 27%. The median dose increase was
50 mg/d (range, 75 mg/d decrease to 375 mg/d increase) and
there was a statistically signiﬁcant decrease in both plasma
clozapine concentration and plasma norclozapine concentra-
tion after transfer in the smoking group. In the non-smoking
group the median prescribed dose before transfer was 250
mg/d and this remained unchanged after transfer (range,
100 mg/d decrease to 125 mg/d increase). We found no
plasma clozapine concentrations >1 mg/L in either the
smoking or non-smoking group post-transfer.
Mental state deterioration was deﬁned as either a wor-
sening of residual symptoms after transfer or emergence of
new psychopathology. Eighteen (39%) patients showed evi-
dence of deterioration in their mental state and of these,
all but one were in the smoking group (P < 0.05; Fisher’s
exact test). The median time to mental state changes was
54.5 days after transfer as recorded in the clinical notes
(range, 6–175 days). Ten patients, all within the smoking
group, experienced an exacerbation of psychotic symptoms
(Table 2). For three patients who experienced increased
psychotic symptoms, the trial leave period was extended as
a consequence. Notably, no patients in the non-smoking
group experienced either a worsening of psychotic symp-
toms or emergence of new psychopathology. The remaining
eight patients, seven of which were in the smoking group and
one in the non-smoking group, experienced non-psychotic
changes in mental state, including increased self-harm, sex-
ual disinhibition, amotivation, agitation and anxiety. In all
cases (N = 18), the mental states of these patients improved
with an increase in clozapine dose and no patients required
readmission to the high-security psychiatric hospital as a
consequence of a change in their mental status.
Discussion
A not unexpected ﬁnding was that most patients commenced
smoking despite being provided with nicotine replacement
therapy and smoking cessation advice both before and
after transfer. Studies have shown that enforced tobacco
abstinence in secure environments has little eﬀect on post-
release smoking status.13,14
There is an established association between tobacco
smoking and the pharmacokinetics of clozapine, with higher
clozapine doses generally required in smokers when com-
pared with non-smokers. A previous evaluation of plasma
clozapine concentrations before and after implementation
of a hospital-wide smoking ban found a mean increase in
plasma clozapine of 36% in non-smokers when outliers
were excluded.15 We found a mean clozapine dose increase
of 23% (median increase, 27%) occurred in smokers pre-
scribed clozapine and this is less than the 40% dose increase
recommended where one or more packs of cigarettes are
used per day16 and less than the recommendation to increase
the clozapine dose by a factor of 1.5 over a period of 2–4
weeks.17 This diﬀerence may be because of the eﬀect of
restricted time periods oﬀ the ward for patients in our sam-
ple, who were in a medium secure unit, which is likely to
have limited their consumption of tobacco. However, it
may also be that clinical teams were cautious in increasing
clozapine doses, or patients were reluctant to take more clo-
zapine, given the observed changes in mental state in the
smoking group.
We found that receiving clinical teams were aware of the
association between plasma clozapine and smoking status
and the need to proactively monitor and adjust doses accord-
ingly. As noted earlier, 72% of patients had plasma clozapine
and norclozapine measured within 1 month of starting trial
leave and this increased to 87% of patients at 3 months post-
transfer. There were nevertheless adverse changes in the
mental state of almost half of patients who had recom-
menced smoking. It is possible these symptoms were sec-
ondary to the observed reduction in plasma clozapine
concentrations. Previous studies investigating the eﬀects of
smoking on mental state have focused on patients with neur-
osis rather than psychosis.18 We found that most patients
experiencing changes in mental state had psychotic symp-
toms, although this may reﬂect the symptoms of this par-
ticular population from a high secure psychiatric unit.
However, structured rating scales were not used in our sur-
vey given the nature of this evaluation.
Our study population was of a modest size and data were
collected over a minimum follow-up period of 6 months,
allowing ample time for changes to clozapine dosing sche-
dules and changes in mental status to have been observed.
A limitation of this study is our use of case notes as a source
of patient data as case notes do not always include all data
that would otherwise have been collected systematically via
a structured interview. Our recording of patient mental sta-
tus before and after smoking resumption is therefore open
to assessment bias. Additionally, the post-transfer plasma
clozapine and norclozapine concentrations used in this
study were not necessarily performed before the recorded
dose adjustments. Given the nature of this study (i.e. a ser-
vice evaluation), we did not control for clozapine dose
when measuring the eﬀect of smoking on clozapine and nor-
clozapine plasma concentrations. It should be noted that the
non-smokers had a statistically signiﬁcant lower norcloza-
pine plasma concentration after transfer; we are unable to
explain this ﬁnding. Finally, we cannot be certain that the
non-smoking patients were entirely abstinent as we relied
on patient notes to classify smoking status; we did not meas-
ure plasma or urine cotinine to conﬁrm smoking status.
This evaluation is a reminder to clinicians that changes
in smoking status may cause marked changes in clozapine
Table 2 Symptoms experienced after transfer
Psychotic symptoms (10 patients)
Paranoid delusions 7
Auditory hallucinations 3
Religious delusions 1
Delusional memory 1
Non-psychotic symptoms (8 patients)
Agitation 3
Anxiety 3
Amotivation 1
Worsening self-harm 1
Sexual disinhibition 1
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plasma concentration, and require substantial adjustments
in clozapine dosing. We anticipate this evaluation will assist
clinicians in the management of patients prescribed cloza-
pine who commence smoking after a period of abstinence
and advocate close monitoring of plasma clozapine concen-
trations, clozapine dose and mental status in patients who
change their smoking status, to minimise the risk of relapse.
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